LONDON (Reuters) - Britain's healthcare cost watchdog NICE has recommended that a new prostate cancer pill from Medivation and Astellas should be used on the state health service.

The draft guidance is conditional on Xtandi being provided at an undisclosed discount to the list price of 2,734.67 pounds for 28 days supply, the National Institute for Health and Clinical Excellence (NICE) said on Friday.

Xtandi, known chemically as enzalutamide, is designed to treat advanced prostate cancer in patients who have previously received chemotherapy.

It is one of four new life-extending prostate cancer drugs that researchers from Britain's Institute of Cancer Research (ICR) have helped to develop in recent years. The others are Johnson & Johnson's Zytiga, Sanofi's Jevtana, and Xofigo from Algeta and Bayer.

Alan Ashworth, chief executive of the ICR, said these drugs offered hope for men after decades in which there had been no options once old-style hormone treatment stopped working.

"What we're seeing now is an unprecedented period of success for prostate cancer research," he said. "It truly is a golden age for prostate cancer drug discovery and development."

Zytiga is already recommended by NICE but Jevtana was rejected as not being cost-effective. The agency has yet to give its verdict on Xofigo, which is on sale in the United States but not yet launched in Europe.

(Reporting by Ben Hirschler; editing by David Evans)

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel